ReNeuron Group plc Notice of Results (0485E)
02 Julio 2021 - 07:00AM
UK Regulatory
TIDMRENE
RNS Number : 0485E
ReNeuron Group plc
02 July 2021
The following amendment has been made to the Notice of Results
announcement released on 2 July at 07:00 under RNS No 9171D.
The link has been corrected.
All other details remain unchanged.
The full amended text is shown below.
ReNeuron Group plc
("ReNeuron" or the "Company")
Notice of Results
Investor Presentation
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, will announce its
preliminary results for the year ended 31 March 2021 on Thursday 8
July 2021.
Investor Briefing
Olav Hellebø, Chief Executive Officer, Rick Beckman, Chief
Medical Officer and John Hawkins, Financial Controller, will be
hosting a live online presentation relating to the preliminary
results via the Investor Meet Company platform at 4.30pm on
Thursday 8 July. The presentation is open to all existing and
potential shareholders.
Investors can sign up to Investor Meet Company for free and
register for the presentation here :
https://www.investormeetcompany.com/reneuron-group-plc/register-investor
Investors who already follow ReNeuron on the Investor Meet
Company platform will automatically be invited.
Questions can be submitted pre-event via your IMC dashboard or
in real time during the presentation, via the "Ask a Question"
function. Whilst the Company may not be in a position to answer
every question it receives, it will address the most prominent
within the confines of information already disclosed to the market
through regulatory notifications. A recording of the presentation,
a PDF of the slides used, and responses to the Q&A session will
be available on the Investor Meet Company platform afterwards.
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Tim Sohal (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus, Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments for disease with significant unmet
needs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the central nervous system and other disorders. The
Company also has the ability through its conditionally immortalised
induced pluripotent stem cell (iPSC) platform to make allogeneic
tissue cells of choice; in-house programmes are currently focused
on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFLLFBFDLEBBZ
(END) Dow Jones Newswires
July 02, 2021 08:00 ET (12:00 GMT)
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024